Literature DB >> 7789652

Defective insulin action on protein and glucose metabolism during chronic hyperinsulinemia in subjects with benign insulinoma.

A Battezzati1, I Terruzzi, G Perseghin, E Bianchi, V Di Carlo, G Pozza, L Luzi.   

Abstract

The ability of chronic endogenous hyperinsulinemia to induce a resistance to insulin action on protein and glucose metabolism was studied in 10 subjects affected by a benign (functioning) insulinoma and 18 healthy subjects by means of infusions of [1-(14)C]leucine and [3-(3)H] glucose. The insulinoma subjects were divided into two groups with moderate (139 +/- 12 pmol/l) (n = 5) and marked (438 +/- 42 pmol/l) (n = 5) hyperinsulinemia and were studied during a euglycemic dextrose infusion. Control subjects were studied postabsorptively and during a low-dose (0.3 mU.kg-1.min-1) (n = 3) and a high-dose (1 mU.kg-1.min-1) (n = 15) euglycemic insulin clamp to match peripheral insulin concentrations with those of insulinoma subjects. In insulinoma subjects there was no correlation among plasma insulin concentration and leucine concentration (r = 0.05), endogenous leucine flux (r = 0.44), hepatic glucose production (r = 0.47), and glucose uptake (r = 0.05). Insulinoma subjects with marked hyperinsulinemia demonstrated a defective suppression of leucine concentrations (100 +/- 11 vs. 65 +/- 5 mumol/l, P < 0.01), endogenous leucine flux (50.1 +/- 6.3 vs. 27.1 +/- 0.9 mumol.m-2.min-1, P < 0.01), and hepatic glucose production (5.4 +/- 2.0 vs. 0.6 +/- 0.6 mumol.kg-1.min-1, P < 0.05), and a defective stimulation of glucose uptake (13.5 +/- 1.6 vs. 41.1 +/- 2.8 mumol.kg-1.min-1, P < 0.001) with respect to normal subjects at a comparable degree of hyperinsulinemia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789652     DOI: 10.2337/diab.44.7.837

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

Review 1.  NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Authors:  M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

2.  Liver-specific reconstitution of CEACAM1 reverses the metabolic abnormalities caused by its global deletion in male mice.

Authors:  Lucia Russo; Harrison T Muturi; Hilda E Ghadieh; Simona S Ghanem; Thomas A Bowman; Hye Lim Noh; Sezin Dagdeviren; Godwin Y Dogbey; Jason K Kim; Garrett Heinrich; Sonia M Najjar
Journal:  Diabetologia       Date:  2017-09-14       Impact factor: 10.122

Review 3.  Why does NAFLD predict type 2 diabetes?

Authors:  Guido Lattuada; Francesca Ragogna; Gianluca Perseghin
Journal:  Curr Diab Rep       Date:  2011-06       Impact factor: 4.810

Review 4.  Viewpoints on the way to a consensus session: where does insulin resistance start? The liver.

Authors:  Gianluca Perseghin
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

5.  Altered Serum Amino Acid and Acylcarnitine Profiles in Hyperinsulinemic Hypoglycemia and Ketotic Hypoglycemia.

Authors:  Zhen-Ran Xu; Xiao-Yi Zhu; Wei Lu; Wei-Hua Sun; Ruo-Qian Cheng; Jin-Wen Ni; Li Xi; Khalid Hussain; Fei-Hong Luo; Miao-Ying Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-08       Impact factor: 5.555

6.  How does exposure to overnutrition in utero lead to childhood adiposity? Testing the insulin hypersecretion hypothesis in the EPOCH cohort.

Authors:  Wei Perng; Megan M Kelsey; Katherine A Sauder; Dana Dabelea
Journal:  Diabetologia       Date:  2021-07-17       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.